Search

Search Constraints

You searched for: Author/Creator Lahn, M.

Search Results

1. 192P Safety and clinical activity of IOA-244: A highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a phase I first-in-human (FIH) study. (December 2022)

2. A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Issue 7 (July 2019)

3. Non-ATP competitive inhibition of PI3Kδ with IOA-244 shows anti-lymphoma activity. (October 2022)